查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1570828

血管收縮素轉化酵素抑制劑市場：按藥物類型、疾病類型、劑型、通路、病患屬性分類 - 2025-2030 年全球預測

Angiotensin Converting Enzyme Inhibitors Market by Drug Type, Disease Type, Dosage Form, Distribution Channel, Patient Demographics - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年血管收縮素轉化酵素抑制劑市值為37億美元，預計到2024年將達到39.2億美元，複合年成長率為6.23%，到2030年將達到56.5億美元。

血管收縮素轉化酵素（ACE）抑制劑是一類主要用於治療高血壓和鬱血性的藥物。 ACE抑制劑抑制血管收縮素I向血管收縮素II的轉化，導致血管舒張和血壓下降。全球高血壓和心血管疾病的流行推動了對 ACE 抑制劑的需求，因此這些藥物對於管理心血管健康至關重要。 ACE抑制劑的用途不僅限於高血壓，還延伸到糖尿病腎臟病和心肌梗塞後的治療，使其在治療方法中變得越來越重要。主要最終用戶包括醫院、診所和私人患者，推動了不同醫療保健環境中的持續需求。推動市場成長的主要因素包括與生活方式相關的健康狀況發病率上升、心血管健康意識增強等。此外，全球人口老化導致慢性心血管疾病盛行率上升，也推動了市場需求。然而，市場面臨一些限制，例如專利到期到期導致學名藥競爭，以及咳嗽和血管性水腫等可能限制患者依從性的副作用。監管障礙和嚴格臨床試驗的需要為市場擴張帶來了進一步的挑戰。儘管如此，仍有開發創新製劑技術的機會，以改善藥物傳遞和患者依從性，包括釋放曲線和與其他高血壓藥物的聯合治療。監控醫療基礎設施正在改善的新興市場也提供了潛在的成長潛力。為了利用這些機會，公司需要注重策略夥伴關係關係以擴大分銷，投資於更新、更有效的配方的研發，並探索用於遠端患者監護和依從性追蹤的數位健康技術。該市場本質上是競爭性的，需要不斷創新並適應法規環境和患者需求，以在全球市場格局中保持相關性和競爭力。

主要市場統計
基準年[2023] 37億美元
預測年份 [2024] 39.2億美元
預測年份 [2030] 56.5億美元
複合年成長率（%） 6.23%

市場動態：快速發展的血管收縮素轉化酵素抑制劑市場的關鍵市場洞察

供需的動態交互作用正在改變血管收縮素轉化酵素抑制劑市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 全球心血管疾病和高血壓盛行率不斷上升，增加了對有效治療方案的需求。
    • 人口老化加劇導致需要血管收縮素轉化酵素抑制劑的慢性疾病盛行率增加
    • 藥物研發進展提高血管收縮素轉化酵素抑制劑的有效性
    • 支持在治療通訊協定中使用血管收縮素轉化酵素抑制劑的政府措施和醫療保健政策
  • 市場限制因素
    • 對血管收縮素轉化酵素抑制劑的需求可能會減少。
    • 與長期使用血管收縮素轉化酵素抑制劑相關的副作用可能會降低患者的依從性
  • 市場機會
    • 先進的配方技術可提高 Ace 抑制劑的生物有效性和標靶遞送
    • 基於基因譜分析客製化 Ace 抑制劑治療的個人化醫療機會
    • 擴大 Ace 抑制劑在腎臟疾病和糖尿病等合併症治療的應用
  • 市場挑戰
    • 來自替代療法和學名藥的競爭挑戰了血管收縮素轉化酵素抑制劑的市場主導地位
    • 病人依從性和教育問題影響血管收縮素轉化酵素抑制劑的療效和市場滲透率

波特五力：駕馭血管收縮素轉化酵素抑制劑市場的策略工具

波特的五力框架是了解血管收縮素轉化酵素抑制劑市場競爭格局的關鍵工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解血管收縮素轉化酵素抑制劑市場的外部影響

外部宏觀環境因素在塑造血管收縮素轉化酵素抑制劑市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解血管收縮素轉化酵素抑制劑市場的競爭狀況

血管收縮素轉化酵素抑制劑市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣血管收縮素轉化酵素抑制劑市場供應商的績效評估

FPNV 定位矩陣是評估血管收縮素轉化酵素抑制劑市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議繪製血管收縮素轉化酵素抑制劑市場的成功之路

對於希望加強在全球市場的影響力的公司來說，對血管收縮素轉化酵素抑制劑市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5.產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球心血管疾病和高血壓的盛行率正在上升，增加了對有效治療方法的需求。
      • 人口老化正在增加需要治療的慢性病的發生率。
      • 藥物研發進展提高血管收縮素轉化酵素抑制劑的有效性
      • 支持在治療通訊協定中使用血管收縮素轉化酵素抑制劑的政府措施和醫療保健政策
    • 抑制因素
      • 增加高血壓替代療法的可用性和選擇可能會減少對血管收縮素轉化酵素抑制劑的需求。
      • 與長期使用血管收縮素轉化酵素抑制劑相關的副作用可能會降低患者的依從性
    • 機會
      • 先進的配方技術可提高 ACE 抑制劑的生物利用度和標靶遞送
      • 基於基因譜分析的客製化 ACE 抑制劑治療的個人化醫療機會
      • 擴大血管張力素轉換酶抑制劑在腎臟病和糖尿病等併發症治療的應用
    • 任務
      • 血管收縮素轉化酵素抑制劑的市場主導地位受到替代療法和學名藥競爭的挑戰
      • 患者依從性和教育問題會影響血管收縮素轉化酵素抑制劑的療效和市場滲透率。
  • 市場區隔分析
  • 波特五力分析
  • PESTLE分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章血管收縮素轉化酵素抑制劑市場：依藥物類型

  • 特異性ACE抑制劑
  • 某些 ACE 抑制劑

第7章血管收縮素轉化酵素抑制劑市場：依疾病類型

  • 心臟病
    • 慢性心臟衰竭
    • 冠狀動脈疾病
  • 高血壓
    • 原發性高血壓
    • 次發性高血壓
  • 腎臟疾病
    • 慢性腎臟病
    • 糖尿病腎臟病

第8章血管收縮素轉化酵素抑制劑市場：按劑型

  • 膠囊
  • 可注射的
  • 藥片

第9章血管收縮素轉化酵素抑制劑市場：按分銷管道

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第10章血管收縮素轉化酵素抑制劑市場：依患者特徵

  • 成人
  • 老年人
  • 兒科的

第11章 美洲血管收縮素轉化酵素抑制劑市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太地區血管收縮素轉化酵素抑制劑市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲血管收縮素轉化酵素抑制劑市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議
Product Code: MRR-1A1A064C05FB

The Angiotensin Converting Enzyme Inhibitors Market was valued at USD 3.70 billion in 2023, expected to reach USD 3.92 billion in 2024, and is projected to grow at a CAGR of 6.23%, to USD 5.65 billion by 2030.

Angiotensin Converting Enzyme (ACE) Inhibitors are a class of medications primarily used to treat hypertension and congestive heart failure. They work by inhibiting the conversion of angiotensin I to angiotensin II, leading to vasodilation and reduced blood pressure. The necessity of ACE inhibitors stems from the global prevalence of hypertension and cardiovascular diseases, positioning these drugs as crucial in managing cardiovascular health. Their application extends beyond hypertension to include diabetic nephropathy and post-myocardial infarction treatment, enhancing their significance in therapeutic regimens. The primary end-users include hospitals, clinics, and individual patients, prompting consistent demand across diverse healthcare settings. Key factors driving market growth include the rising incidence of lifestyle-related health conditions and increasing awareness about cardiovascular health. Additionally, the aging global population underpinning a higher prevalence of chronic cardiovascular conditions propels market demand. However, the market faces limitations such as patent expirations leading to generic drug competition, and side effects like cough and angioedema, which may limit patient compliance. Regulatory hurdles and the need for rigorous clinical trials further challenge market expansion. Nonetheless, opportunities exist in developing innovative formulation techniques to improve drug delivery and patient adherence, such as release profiles and combination therapies with other antihypertensives. Monitoring emerging markets where healthcare infrastructure is improving also offers potential growth avenues. To capitalize on these opportunities, companies should focus on strategic partnerships for expanded distribution, invest in research and development for newer, more efficient drug formulations, and explore digital health technologies for remote patient monitoring and adherence tracking. The market is inherently competitive, necessitating constant innovation and adaptation to regulatory environments and patient needs, thus maintaining relevance and competitive advantage in the global market landscape.

KEY MARKET STATISTICS
Base Year [2023] USD 3.70 billion
Estimated Year [2024] USD 3.92 billion
Forecast Year [2030] USD 5.65 billion
CAGR (%) 6.23%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Angiotensin Converting Enzyme Inhibitors Market

The Angiotensin Converting Enzyme Inhibitors Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of cardiovascular diseases and hypertension globally driving demand for effective treatment options
    • Growing aging population contributing to increased incidence of chronic conditions requiring angiotensin converting enzyme inhibitors
    • Advancements in pharmaceutical research and development enhancing efficacy of angiotensin converting enzyme inhibitors
    • Government initiatives and healthcare policies supporting the use of angiotensin converting enzyme inhibitors in treatment protocols
  • Market Restraints
    • Increasing availability and preference for alternative treatments for hypertension may reduce demand for angiotensin converting enzyme inhibitors
    • Adverse side effects associated with prolonged use of angiotensin converting enzyme inhibitors may reduce patient adherence
  • Market Opportunities
    • Advanced formulation techniques for improved bioavailability and targeted delivery of ace inhibitors
    • Opportunities in personalized medicine with customized ace inhibitor treatments based on genetic profiling
    • Growing application of ace inhibitors in managing comorbid conditions such as kidney disease and diabetes
  • Market Challenges
    • Competition from alternative therapies and generic drugs challenges the market dominance of angiotensin converting enzyme inhibitors
    • Patient adherence and education issues impact the effectiveness and market uptake of angiotensin converting enzyme inhibitors

Porter's Five Forces: A Strategic Tool for Navigating the Angiotensin Converting Enzyme Inhibitors Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Angiotensin Converting Enzyme Inhibitors Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Angiotensin Converting Enzyme Inhibitors Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Angiotensin Converting Enzyme Inhibitors Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Angiotensin Converting Enzyme Inhibitors Market

A detailed market share analysis in the Angiotensin Converting Enzyme Inhibitors Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Angiotensin Converting Enzyme Inhibitors Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Angiotensin Converting Enzyme Inhibitors Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Angiotensin Converting Enzyme Inhibitors Market

A strategic analysis of the Angiotensin Converting Enzyme Inhibitors Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Angiotensin Converting Enzyme Inhibitors Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Allergan plc, Amgen Inc., AstraZeneca PLC, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Mylan N.V., Novartis AG, Pfizer Inc., Roche Holding AG, Sanofi S.A., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Angiotensin Converting Enzyme Inhibitors Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Type, market is studied across Non-Specific ACE Inhibitors and Specific ACE Inhibitors.
  • Based on Disease Type, market is studied across Heart Diseases, Hypertension, and Kidney Diseases. The Heart Diseases is further studied across Chronic Heart Failure and Coronary Artery Disease. The Hypertension is further studied across Primary Hypertension and Secondary Hypertension. The Kidney Diseases is further studied across Chronic Kidney Diseases and Diabetic Nephropathy.
  • Based on Dosage Form, market is studied across Capsules, Injectable, and Tablets.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Patient Demographics, market is studied across Adult, Geriatric, and Pediatric.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of cardiovascular diseases and hypertension globally driving demand for effective treatment options
      • 5.1.1.2. Growing aging population contributing to increased incidence of chronic conditions requiring angiotensin converting enzyme inhibitors
      • 5.1.1.3. Advancements in pharmaceutical research and development enhancing efficacy of angiotensin converting enzyme inhibitors
      • 5.1.1.4. Government initiatives and healthcare policies supporting the use of angiotensin converting enzyme inhibitors in treatment protocols
    • 5.1.2. Restraints
      • 5.1.2.1. Increasing availability and preference for alternative treatments for hypertension may reduce demand for angiotensin converting enzyme inhibitors
      • 5.1.2.2. Adverse side effects associated with prolonged use of angiotensin converting enzyme inhibitors may reduce patient adherence
    • 5.1.3. Opportunities
      • 5.1.3.1. Advanced formulation techniques for improved bioavailability and targeted delivery of ace inhibitors
      • 5.1.3.2. Opportunities in personalized medicine with customized ace inhibitor treatments based on genetic profiling
      • 5.1.3.3. Growing application of ace inhibitors in managing comorbid conditions such as kidney disease and diabetes
    • 5.1.4. Challenges
      • 5.1.4.1. Competition from alternative therapies and generic drugs challenges the market dominance of angiotensin converting enzyme inhibitors
      • 5.1.4.2. Patient adherence and education issues impact the effectiveness and market uptake of angiotensin converting enzyme inhibitors
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Angiotensin Converting Enzyme Inhibitors Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Non-Specific ACE Inhibitors
  • 6.3. Specific ACE Inhibitors

7. Angiotensin Converting Enzyme Inhibitors Market, by Disease Type

  • 7.1. Introduction
  • 7.2. Heart Diseases
    • 7.2.1. Chronic Heart Failure
    • 7.2.2. Coronary Artery Disease
  • 7.3. Hypertension
    • 7.3.1. Primary Hypertension
    • 7.3.2. Secondary Hypertension
  • 7.4. Kidney Diseases
    • 7.4.1. Chronic Kidney Diseases
    • 7.4.2. Diabetic Nephropathy

8. Angiotensin Converting Enzyme Inhibitors Market, by Dosage Form

  • 8.1. Introduction
  • 8.2. Capsules
  • 8.3. Injectable
  • 8.4. Tablets

9. Angiotensin Converting Enzyme Inhibitors Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacies
  • 9.3. Online Pharmacies
  • 9.4. Retail Pharmacies

10. Angiotensin Converting Enzyme Inhibitors Market, by Patient Demographics

  • 10.1. Introduction
  • 10.2. Adult
  • 10.3. Geriatric
  • 10.4. Pediatric

11. Americas Angiotensin Converting Enzyme Inhibitors Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Angiotensin Converting Enzyme Inhibitors Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Angiotensin Converting Enzyme Inhibitors Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Allergan plc
  • 3. Amgen Inc.
  • 4. AstraZeneca PLC
  • 5. Bayer AG
  • 6. Boehringer Ingelheim GmbH
  • 7. Bristol-Myers Squibb Company
  • 8. Daiichi Sankyo Company, Limited
  • 9. Eli Lilly and Company
  • 10. Gilead Sciences, Inc.
  • 11. GlaxoSmithKline plc
  • 12. Johnson & Johnson
  • 13. Merck & Co., Inc.
  • 14. Mylan N.V.
  • 15. Novartis AG
  • 16. Pfizer Inc.
  • 17. Roche Holding AG
  • 18. Sanofi S.A.
  • 19. Takeda Pharmaceutical Company Limited
  • 20. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET RESEARCH PROCESS
  • FIGURE 2. ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET DYNAMICS
  • TABLE 7. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY NON-SPECIFIC ACE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY SPECIFIC ACE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY CHRONIC HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PRIMARY HYPERTENSION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY SECONDARY HYPERTENSION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY CHRONIC KIDNEY DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DIABETIC NEPHROPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
  • TABLE 56. BRAZIL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 60. CANADA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. CANADA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. CANADA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
  • TABLE 63. CANADA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
  • TABLE 64. CANADA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 65. CANADA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 66. CANADA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 68. MEXICO ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. MEXICO ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. MEXICO ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
  • TABLE 71. MEXICO ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
  • TABLE 72. MEXICO ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 73. MEXICO ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 74. MEXICO ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. MEXICO ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 76. UNITED STATES ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. UNITED STATES ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. UNITED STATES ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
  • TABLE 79. UNITED STATES ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
  • TABLE 80. UNITED STATES ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 81. UNITED STATES ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 82. UNITED STATES ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. UNITED STATES ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 84. UNITED STATES ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 94. AUSTRALIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. AUSTRALIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. AUSTRALIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
  • TABLE 97. AUSTRALIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
  • TABLE 98. AUSTRALIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 99. AUSTRALIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 100. AUSTRALIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. AUSTRALIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 102. CHINA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. CHINA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. CHINA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
  • TABLE 105. CHINA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
  • TABLE 106. CHINA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 107. CHINA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 108. CHINA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. CHINA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 110. INDIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. INDIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. INDIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
  • TABLE 113. INDIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
  • TABLE 114. INDIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 115. INDIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 116. INDIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 117. INDIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 118. INDONESIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. INDONESIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. INDONESIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
  • TABLE 121. INDONESIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
  • TABLE 122. INDONESIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 123. INDONESIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 124. INDONESIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 125. INDONESIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 126. JAPAN ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. JAPAN ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. JAPAN ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
  • TABLE 129. JAPAN ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
  • TABLE 130. JAPAN ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 131. JAPAN ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 132. JAPAN ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. JAPAN ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 134. MALAYSIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. MALAYSIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. MALAYSIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
  • TABLE 137. MALAYSIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
  • TABLE 138. MALAYSIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 139. MALAYSIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 140. MALAYSIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 141. MALAYSIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 142. PHILIPPINES ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. PHILIPPINES ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. PHILIPPINES ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
  • TABLE 145. PHILIPPINES ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
  • TABLE 146. PHILIPPINES ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 147. PHILIPPINES ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 148. PHILIPPINES ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 149. PHILIPPINES ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 150. SINGAPORE ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. SINGAPORE ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. SINGAPORE ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
  • TABLE 153. SINGAPORE ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
  • TABLE 154. SINGAPORE ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 155. SINGAPORE ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 156. SINGAPORE ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 157. SINGAPORE ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 158. SOUTH KOREA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. SOUTH KOREA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. SOUTH KOREA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH KOREA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH KOREA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH KOREA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH KOREA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH KOREA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 166. TAIWAN ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. TAIWAN ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. TAIWAN ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
  • TABLE 169. TAIWAN ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
  • TABLE 170. TAIWAN ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 171. TAIWAN ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 172. TAIWAN ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 173. TAIWAN ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 174. THAILAND ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. THAILAND ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. THAILAND ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
  • TABLE 177. THAILAND ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
  • TABLE 178. THAILAND ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 179. THAILAND ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 180. THAILAND ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 181. THAILAND ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 182. VIETNAM ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. VIETNAM ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. VIETNAM ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
  • TABLE 185. VIETNAM ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
  • TABLE 186. VIETNAM ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 187. VIETNAM ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 188. VIETNAM ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 189. VIETNAM ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 199. DENMARK ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. DENMARK ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. DENMARK ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
  • TABLE 202. DENMARK ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
  • TABLE 203. DENMARK ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 204. DENMARK ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 205. DENMARK ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 206. DENMARK ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 207. EGYPT ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. EGYPT ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. EGYPT ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
  • TABLE 210. EGYPT ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
  • TABLE 211. EGYPT ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 212. EGYPT ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 213. EGYPT ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 214. EGYPT ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 215. FINLAND ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. FINLAND ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. FINLAND ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
  • TABLE 218. FINLAND ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
  • TABLE 219. FINLAND ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 220. FINLAND ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 221. FINLAND ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 222. FINLAND ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 223. FRANCE ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. FRANCE ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. FRANCE ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
  • TABLE 226. FRANCE ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
  • TABLE 227. FRANCE ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 228. FRANCE ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 229. FRANCE ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 230. FRANCE ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 231. GERMANY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. GERMANY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. GERMANY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
  • TABLE 234. GERMANY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
  • TABLE 235. GERMANY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 236. GERMANY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 237. GERMANY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 238. GERMANY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 239. ISRAEL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 240. ISRAEL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 241. ISRAEL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
  • TABLE 242. ISRAEL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
  • TABLE 243. ISRAEL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 244. ISRAEL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 245. ISRAEL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 246. ISRAEL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 247. ITALY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 248. ITALY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 249. ITALY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
  • TABLE 250. ITALY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
  • TABLE 251. ITALY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 252. ITALY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 253. ITALY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 254. ITALY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 255. NETHERLANDS ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 256. NETHERLANDS ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 257. NETHERLANDS ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
  • TABLE 258. NETHERLANDS ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
  • TABLE 259. NETHERLANDS ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 260. NETHERLANDS ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 261. NETHERLANDS ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 262. NETHERLANDS ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 263. NIGERIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 264. NIGERIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 265. NIGERIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
  • TABLE 266. NIGERIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
  • TABLE 267. NIGERIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 268. NIGERIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 269. NIGERIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 270. NIGERIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 271. NORWAY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 272. NORWAY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 273. NORWAY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
  • TABLE 274. NORWAY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
  • TABLE 275. NORWAY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 276. NORWAY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 277. NORWAY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 278. NORWAY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 279. POLAND ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 280. POLAND ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)

TABLE 28